Parainfluenza Virus type 1 NC Antibody (7F5): sc-65934

Parainfluenza Virus type 1 NC Antibody (7F5) is a mouse monoclonal IgG1 antibody that detects the Parainfluenza Virus type 1 NC protein by western blotting (WB). Anti-Parainfluenza Virus type 1 NC antibody (7F5) is available as a non-conjugated format. The Nucleocapsid (NC) protein plays a crucial role in viral life cycles by encapsulating viral RNA genomes and supporting assembly and budding of new virions. NC protein protects viral RNA from degradation while facilitating interactions with other viral proteins necessary for replication and transcription. Understanding NC protein function remains vital for developing antiviral strategies, as targeting NC protein could inhibit viral replication and spread. Parainfluenza viruses, including HPIV-1, cause significant respiratory illnesses, particularly in young children, making NC protein studies critical for public health.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Parainfluenza Virus type 1 NC Antibody (7F5) References:

1. Sequence analysis of the Washington/1964 strain of human parainfluenza virus type 1 (HPIV1) and recovery and characterization of wild-type recombinant HPIV1 produced by reverse genetics.  |  Newman, JT., et al. 2002. Virus Genes. 24: 77-92. PMID: 11928991
2. The long noncoding region of the human parainfluenza virus type 1 f gene contributes to the read-through transcription at the m-f gene junction.  |  Bousse, T., et al. 2002. J Virol. 76: 8244-51. PMID: 12134030
3. Generation of recombinant human parainfluenza virus type 1 vaccine candidates by importation of temperature-sensitive and attenuating mutations from heterologous paramyxoviruses.  |  Newman, JT., et al. 2004. J Virol. 78: 2017-28. PMID: 14747566
4. Human parainfluenza virus type I (HPIV1) vaccine candidates designed by reverse genetics are attenuated and efficacious in African green monkeys.  |  Bartlett, EJ., et al. 2005. Vaccine. 23: 4631-46. PMID: 15951066
5. Introducing point and deletion mutations into the P/C gene of human parainfluenza virus type 1 (HPIV1) by reverse genetics generates attenuated and efficacious vaccine candidates.  |  Bartlett, EJ., et al. 2006. Vaccine. 24: 2674-84. PMID: 16364511
6. Attenuating mutations in the P/C gene of human parainfluenza virus type 1 (HPIV1) vaccine candidates abrogate the inhibition of both induction and signaling of type I interferon (IFN) by wild-type HPIV1.  |  Van Cleve, W., et al. 2006. Virology. 352: 61-73. PMID: 16750233
7. Mutation at residue 523 creates a second receptor binding site on human parainfluenza virus type 1 hemagglutinin-neuraminidase protein.  |  Bousse, T. and Takimoto, T. 2006. J Virol. 80: 9009-16. PMID: 16940513
8. Human parainfluenza viruses hPIV1 and hPIV3 bind oligosaccharides with alpha2-3-linked sialic acids that are distinct from those bound by H5 avian influenza virus hemagglutinin.  |  Amonsen, M., et al. 2007. J Virol. 81: 8341-5. PMID: 17522226